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Abstract: 
 
Earlier studies have shown the cancer chemopreventive efficacy of silymarin and its semi‐
purified constituent silibinin against prostate cancer (PCa), but the efficacy of other constituents 
of silymarin is largely unknown. In the present study, we assessed the in vivogrowth inhibitory 
efficacy of one such constituent isosilibinin (a 50:50 mixture of isosilybin A and isosilybin B) in 
comparison with silymarin and silibinin in human PCa DU145 xenograft in athymic nude mice. 
Isosilibinin feeding (200 mg/kg body weight per day) significantly inhibited the growth of 
xenograft after 53 days of treatment (p ≤ 0.005), which was equally or slightly better effective 
than silymarin and silibinin, respectively. Treatment with isosilibinin, silymarin and silibinin was 
stopped after 53 days and tumor volume was measured till 77 days. After 24 days of treatments 
withdrawal, tumor volume remain decreased, however, it was statistically significant only with 
isosilibinin (p ≤ 0.05), suggesting its prolonged effect. Biomarker analysis showed that 
isosilibinin, silymarin and silibinin treatment for 53 days significantly inhibited the 
immunoreactivity for proliferating cell nuclear antigen (PCNA), microvessel density (CD31) and 
vascular endothelial growth factor along with significant increase in apoptotic cell population. 
The PCNA levels in tumors remained significantly low even after 24 days of treatments 
withdrawal. Western blot analysis of tumor tissue suggested that these flavonolignan 
formulations differentially alter the expression of cell cycle regulatory molecules, cyclins and 
Cdks. Overall, the results of present study suggest that isosilibinin has comparatively better 
efficacy against PCa and should be further analyzed for its clinical utility.  
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Article:  
 
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men in the western 
world including United States.1 According to American Cancer Society report, about 218,890 
incidences (29% of total estimated new cases) and 27,050 deaths (9% of total estimated deaths) 
due to PCa were estimated in American men in the year 2007.1 In initial stages, PCa is androgen‐
dependent and treatment options include hormone ablation therapy, surgery, radio‐ and chemo‐
therapy.2-4 These treatments only delay the recurrence of the lethal hormone‐refractory disease 
and patients have poor survival afterwards.3, 4 For the late stage hormone‐refractory PCa, 
chemotherapeutic drugs offer little survival benefit.3, 4 Further, all these treatments have 
significant side effects including impotence and incontinence that adversely affect the quality of 
life for patients. These limitations of the current therapeutic regimens suggest the need for 
alterative strategies to decrease the morbidity and mortality due to this malignancy. In this 
regard, prevention and therapeutic intervention by phytochemicals has been suggested as a newer 
dimension in the arena of cancer management. Epidemiological and preclinical studies have also 
suggested the anticancer efficacy of phytochemicals, which are rich source of polyphenolic 
compounds.5-7 
 
Silymarin is a crude mixture of polyphenolic compounds and is obtained mainly from milk 
thistle (Silybum marianum) and artichoke (Cynara scolymus), members of the Asteraceae family. 
Silymarin is widely known for its hepatoprotective property both in animal models of hepatic 
injuries and in humans.8-10 In the last decade, anticancer efficacy of silymarin and its most active 
known constituent, silibinin, have been reported against various epithelial cancers namely skin, 
colon, liver, lung, bladder, prostate, breast, among others.11-15 Despite these advances not much 
effort has been made to analyze the anticancer efficacy of other constituents of silymarin. 
Largely, these studies have examined milk thistle as either a complex mixture of at least 8 
compounds, termed “silymarin,” which is a series of 7 structurally‐related flavonolignans and the 
flavonoid, taxifolin16 or as an approximately equal mixture of the 2 most prominent 
flavonolignans, termed silibinin, which consists of the diastereoisomers, silybin A and silybin 
B.16-18 The focus of these studies was the in vivoeffect of isosilibinin, which consists of the 
diastereoisomers, isosilybin A and isosilybin B16relative to silymarin and silibinin (Fig. 1a). The 
nomenclature of silymarin and related constituents is quite complex and has been reviewed 
recently.16 
 
We have reported that these pure compounds from silymarin have differential anticancer effects 
on various biological and molecular endpoints.18, 19 In general, isosilybin B and isosilybin A 
were found to be most effective in inhibiting the cell survival, prostate specific antigen (PSA) 
secretion, androgen receptor level and topoisomerase IIα promoter activity in human PCa 
cells.18, 20 Further studies have suggested that these 2 compounds significantly inhibit the cell 
growth via modulating cell cycle regulatory molecules in human PCa LNCaP and 22Rv1 
cells.21 These in vitro studies in androgen‐dependent and androgen‐independent PCa cells clearly 
suggest the superior efficacy of the isosilibinin fraction relative to other constituents of 
                                                          
  Abbreviations: CD31, cluster of differentiation 31; CDK, cyclin‐dependent kinase; Isosil, Isosilibinin; PCa, 
prostate cancer; PCNA, proliferating cell nuclear antigen; RPMI, Roswell Park Memorial Institute; SB, silibinin; 
SEM, standard error of mean; SM, silymarin; TUNEL, terminal deoxynucleotidyl transferase‐mediated dUTP nick‐
end labeling; VEGF, vascular endothelial growth factor. 
silymarin. Therefore, the present study was designed, for the first time, to examine the in 
vivo efficacy of isosilibinin against DU145 hormone‐independent human prostate xenograft 
growth in nude mice, and its comparison with silymarin and silibinin. Additionally, we examined 
the effect of these 3 formulations on in vivo biomarkers for proliferation, apoptosis and 
angiogenesis along with associated alterations in the expression of cell cycle regulatory 
molecules in tumor tissue. We also monitored the effect of treatments withdrawal on tumor 
growth kinetics. The findings of the present study identified in vivo anti‐PCa efficacy of 
isosilibinin which was relatively better than silibinin and silymarin. 
 
 
Figure 1. Effect of isosilibinin, silymarin and silibinin treatments on the body weight and diet consumption by 
athymic nude mice. (a) Chemical structure of isosilybin A and isosilybin B. (b) Experimental design for the 
xenograft experiment. (c) Food intake was recorded throughout the experiment and the diet consumption/mouse/day 
(g) is plotted as a function of time (days) for each group. Each point is a mean value of 14–15 mice till 53 days and 
6–8 mice during 53–77 days. (d) Body weight of each mouse in different groups was recorded twice a week 
throughout the experiment and is plotted as a function of time (days) for each group. Each point is a mean value of 
14–15 mice till 53 days and 6–8 mice during 53–77 days. 
 
Material and methods 
 
Cell line and reagents 
 
DU145 human prostate carcinoma cells were obtained from the American Type Culture 
Collection (Manassas, VA) and grown in RPMI 1640 with 10% fetal bovine serum, 100 units/ml 
penicillin and 100 μg/ml streptomycin at 37°C in a humidified 95% air and 5% CO2atmosphere. 
DU145 cells grown as monolayer were harvested by brief incubation with 0.25% trypsin‐EDTA 
solution and used for xenograft implantation in nude mice. RPMI 1640 media and other cell 
culture materials were from Invitrogen Corporation (Gaithersberg, MD). Matrigel was from BD 
Biosciences (New Bedford, MA). TUNEL (Terminal deoxynucleotidyl transferase‐mediated 
dUTP nick‐end labeling) assay kit was from Promega Corporation (Madison, WI). Harris 
hematoxylin, carboxymethylcellulose (CMC), 3,3′‐diaminobenzidine (DAB) and antibody for β‐
actin were from Sigma (St. Louis, MO). Streptavidin, primary antibody for proliferating cell 
nuclear antigen (PCNA) and biotinylated anti‐mouse secondary antibody were from Dako 
(Carpinteria, CA). Primary antibody for CD31 was from Abcam (Cambridge, MA). Antibodies 
for Cdk2, Cdk4, Cdk6, cyclin D1, cyclin D3, cyclin E, cyclin A and vascular endothelial growth 
factor (VEGF) were from Santa Cruz Biotechnology (Santa Cruz, CA). Normal goat serum and 
biotinylated anti‐rabbit secondary antibody were also from Santa Cruz Biotechnology (Santa 
Cruz, CA). Silymarin was obtained as a powdered extract (1 kg; Product No. 345066, Lot No. 
37501) of the seeds (achenes) of Silybum marianum (L.) Gaertn. from Euromed, S.A. 
(Barcelona, Spain), which is a part of the Madaus Group (Cologne, Germany). The purification 
of silibinin (a 49:51 mixture of silybin A and silybin B, respectively) and isosilibinin (a 49:51 
mixture of isosilybin A and isosilybin B, respectively) from silymarin has been described in 
detail.22 Briefly, chromatographic fractions enriched in the compounds of interest were pooled 
until the ratio of the 2 desired diastereoisomers was as noted. Final purity was determined by 
HPLC as described,22 and each sample was >99.5% pure. 
 
Animals and diet 
 
Athymic (nu/nu) male nude mice were obtained from the National Cancer Institute (Bethesda, 
MD) and housed in our animal care facility at standard laboratory conditions (in laminar airflow 
cabinets under pathogen‐free conditions with a 12 hr light/12 hr dark schedule) and fed 
autoclaved Harlan Teklad Sterilizable rodent diet and water ad libitum. All the protocols used 
were approved by the Institutional Animal care and Use Committee of the University of 
Colorado Denver. 
 
Experimental design for tumor xenograft study 
 
Athymic nude mice were kept in the animal house facility for 1 week for acclimatization. To 
determine the effect of isosilibinin, silymarin and silibinin on prostate tumor growth, DU145 
tumors were grown subcutaneously (s.c.) in nude mice. About 3.5 million DU145 cells were 
suspended in 0.05 ml of serum‐free medium (RPMI), mixed with 0.05 ml of matrigel and were 
s.c. injected in the right flank of each mouse to initiate tumor growth (Fig. 1b). The following 
day after xenograft implantation, nude mice were randomly divided in to 4 groups: Group I was 
treated with 200 μl of 0.5% CMC (vehicle control); Group II was treated with 200 mg/kg body 
weight of isosilibinin (200 μl in 0.5% CMC); Group III was treated with 200 mg/kg body weight 
of silymarin (200 μl in 0.5% CMC); Group IV was treated with 200 mg/kg body weight of 
silibinin (200 μl in 0.5% CMC). These treatments were through oral gavage route (5 days/week) 
and initiated the day after xenograft implantation (day 0) (Fig. 1b). At the end of 53 days after 
xenograft implantation, 7 animals from each group were sacrificed with lethal ketamine injection 
and tumors were harvested and used for immunohistochemical analysis (Fig. 1b). The remainder 
of the animals in each group were left without any further treatment and monitored until 77 days 
and then sacrificed and tumor tissues analyzed (Fig. 1b). Throughout the experiment, food 
consumption and animal body weight were monitored twice weekly. Once the tumor xenograft 
started growing, their sizes were measured twice weekly in 2 dimensions using a digital caliper. 
The tumor volume was calculated by the formula: 0.5236 L1(L2),2 where L1 is long diameter, 
and L2 is short diameter. At the termination of these studies, each tumor was carefully dissected 
and weighed. All small tumors and a piece of large tumors were fixed and processed for 
immunohistochemical analysis. The rest of the tumor tissue was snap frozen in liquid nitrogen 
and stored at −80°C for immunoblot analyses. 
 
Immunohistochemical detection of PCNA in tumors 
 
Tumor samples were fixed in 10% buffered‐formalin for 12 hr and processed conventionally. 
The paraffin‐embedded tumor sections (5 μm‐thick) were heat immobilized, deparaffinized using 
xylene, and rehydrated in a graded series of ethanol with a final wash in distilled water. Antigen 
retrieval was performed using 10mM citrate buffer (pH 6.0) in a microwave for 15 min at full 
and 20% power levels, respectively. Endogenous peroxidase activity was blocked by immersing 
the sections in 3.0% H2O2 in methanol (v/v), followed by 3 changes in 10 mM PBS (pH 7.4). 
The sections were then incubated with mouse monoclonal anti‐PCNA antibody (1:400) for 2 hr 
at room temperature in a humidity chamber and overnight at 4°C. Negative controls were treated 
only with PBS under identical conditions. The sections were then incubated with biotinylated 
rabbit anti‐mouse antibody (1:200) for 1 hr at room temperature. Thereafter, following wash with 
PBS, sections were incubated with conjugated horseradish peroxidase‐streptavidin for 45 min at 
room temperature in a humidity chamber. The sections were then incubated with DAB working 
solution for 5 min at room temperature, counterstained with diluted Harris hematoxylin for 2 
min, and rinsed in Scott's water. Finally, proliferating cells were quantified by counting the 
PCNA‐positive cells and the total number of cells at 5 arbitrarily selected fields at 400× 
magnification. The proliferation index (per 400× microscopic field) was determined as number 
of PCNA‐positive cells × 100/total number of cells. 
 
In situ apoptosis detection by TUNEL staining 
 
Paraffin‐embedded, 5 μm‐thick sections were also used to identify apoptotic cells by staining 
using TUNEL assay kit as per vendor's protocol. The extent of apoptosis was evaluated by 
counting the TUNEL‐positive cells (brown‐stained) as well as the total number of cells in 5 
randomly selected fields at 400× magnification. The apoptotic index was calculated as (number 
of apoptotic cells × 100)/total number of cells. 
 
Immunohistochemical analysis of tumors for CD31 expression 
 
The staining procedure for CD31 (an endothelial cell‐specific antigen also known as platelet 
endothelial cell adhesion molecule‐1) was similar to that of PCNA staining with some 
modifications. Before incubation with primary antibody, tumor section were incubated with 
normal goat serum for 30 min. Tumor sections were incubated for 2 hr at room temperature and 
overnight at 4°C with goat anti‐rabbit CD31 polyclonal antibody (1:50). Then sections were 
incubated with biotinylated goat anti‐rabbit secondary antibody (1:200) followed by streptavidin‐
conjugated horseradish peroxidase (1:300). Antigen‐antibody complexes were visualized by 
incubation with DAB substrate and counterstained with diluted Harris hematoxylin. 
Microvessels stained with CD31 (brown) were quantified in 5 random microscopic (400× 
magnification) fields per tumor. 
 
Immunohistochemical analysis of tumors for VEGF expression 
 
The staining procedure for VEGF was similar to that of PCNA staining using specific primary 
antibodies. Briefly, tumor sections were incubated with rabbit anti‐VEGF (1:100) followed by 
incubation with appropriate biotinylated secondary antibody (1:200) and streptavidin (1:200). 
Finally, antigen‐antibody complexes were visualized by peroxidase reaction with DAB substrate 
and counterstained with diluted Harris hematoxylin. VEGF immunoreactivity (represented by 
brown staining) was analyzed in 5 random areas for each tumor tissue and was scored as 0+ (no 
staining), 1+ (weak staining), 2+ (moderate staining), 3+ (strong staining), 4+ (very strong 
staining). 
 
Immunoblot analysis of tissue lysates 
 
Total tissue lysates were prepared as described earlier.11 Protein concentration in tissue lysates 
was determined with Bio‐Rad detergent‐compatible protein assay kit (Bio‐Rad Laboratories) by 
the Lowry method, and 50–70 μg of protein/sample was then subjected to immunoblot analysis 
as described previously.11 Membranes were probed for the protein abundance of desired 
molecules using specific primary antibodies followed by the appropriate peroxidase‐conjugated 
secondary antibody and visualized by ECL detection. To ensure equal protein loading, each 
membrane was stripped and reprobed with anti‐β‐actin antibody, which was also used to 
normalize for differences in protein loading in densitometric analyses. 
 
Immunohistochemical and statistical analyses 
 
All the microscopic immunohistochemical analyses were performed using a Zeiss Axioscope 2 
microscope (Carl Zeiss) and photographs were captured with a Carl Zeiss AxioCam MrC5 
camera with Axiovision Rel 4.5 software. Western blots were scanned with Adobe Photoshop 
6.0 (Adobe Systems, San Jose, CA), and the mean density of each band was analyzed by the 
Scion Image program (National Institutes of Health, Bethesda, MD). In each case, blots were 
subjected to multiple exposures on the film to make sure that the band density is in the linear 
range. All statistical analyses were carried out with Sigma Stat software version 2.03 (Jandel 
Scientific). Mean and SEM were used to describe the quantitative data. The statistical 
significance of difference between control and treated‐groups was determined by Student's t‐test 
or 1 way ANOVA followed by Bonferrroni t test for pair‐wise multiple comparisons and p < 
0.05 was considered significant. 
 
Results 
 
General observations 
 
At the time of necropsy, all animals were examined for gross pathology, and we did not observe 
any signs of abnormality in all the vital organs examined such as liver, lung, heart and kidney. 
The administration of isosilibinin, silymarin or silibinin (200 mg/kg body weight in CMC, 5 
d/wk) through oral gavage did not cause any change in the diet consumption pattern of mice 
during the treatments (53 days) or after the withdrawal of treatments for 24 days (Fig. 1c). There 
were no significant differences between the mean body weights of mice in all the groups during 
the experimental period or during the withdrawal of the treatments (Fig. 1d). We also did not 
observe any significant difference among various groups in the ratio of prostate weight/body 
weight (data not shown). 
 
 
Figure 2. Effect of isosilibinin, silymarin and silibinin treatments on DU145 tumor xenograft growth in athymic 
nude mice. Approximately 3.5 million DU145 cells were s.c. injected in the right flank of each mouse to initiate 
ectopic prostate tumor growth as described in “Material and methods”. The dose of isosilibinin or silymarin or 
silibinin was 200 mg/kg body weight. (a) Tumor volume in isosilibinin, silymarin and silibinin treated groups was 
measured twice weekly throughout the experiment using the formula: 0.5236 L1(L2).2 Each value represents mean 
and ± SEM (error bars) of 14–15 mice for each group. (b)Treatment of isosilibinin, silymarin and silibinin was 
stopped after 53 days and tumor volume was measured twice weekly till 77 days. Each value represents mean and ± 
SEM (error bars) of 6–8 mice for each group. The tumor volume data was also used for regression analysis after 
plotting a scatter diagram and the rate of tumor growth was measured from the equation shown in panel c. 
Abbreviations: C, control; Isosil, isosilibinin; SM, silymarin; SB, silibinin. 
 
Isosilibinin, silymarin and silibinin inhibit prostate cancer xenograft growth 
 
All 3 formulations significantly inhibited the tumor volume during 53 days of treatment. 
Isosilibinin treatment resulted in significant decreases in mean tumor volumes 18 days onwards 
(p = 0.01; n = 15), whereas silymarin (n = 14) and silibinin (n = 15) treatment resulted in 
significant decreases in mean tumor volume only after 25 days of treatment (p ≤ 0.001; n = 15) 
(Fig. 2a). After 53 days of treatment, isosilibinin treatment resulted in 64.10% decrease in the 
tumor volume (p = 0.005; n = 15); silymarin treatment resulted in 63.64% decrease in the tumor 
volume (p = 0.01; n = 14); whereas silibinin treatment resulted in 55.47% decrease in the tumor 
volume (p = 0.05; n = 15) (Fig. 2a). These results showed the efficacy of these compounds in 
inhibiting the growth of PCa DU145 cells xenograft in nude mice. 
 
Inhibitory effects of isosilibinin on tumor growth is more lasting compared to silymarin and 
silibinin 
 
The treatments with isosilibinin, silymarin or silibinin were stopped after 53 days, and then 7 
mice from each group was sacrificed, whereas the rest of the animals were monitored for tumor 
growth for 24 days without treatment. Even after 24 days of treatment withdrawal, there was 
66.4% decrease in tumor volume with isosilibinin (p = 0.05; n = 8), and 61.8% with silymarin 
(n = 7) and 55.6% with silibinin (n = 8), but the data for silymarin and silibinin did not achieve 
statistical significance due to large variation in tumor size (Fig. 2b). The regression analysis 
showed that the rate of tumor growth was slowest in isosilibinin group followed by silymarin and 
silibinin (equations shown in Fig. 2c), but these differences in the rate of tumor growth did not 
achieve statistical significance. 
 
Isosilibinin, silymarin and silibinin inhibit proliferation of DU145 xenograft cells 
 
Next, we analyzed the effect of these compounds on biochemical marker of proliferation in PCa 
xenograft tissue. The immunohistochemical analysis of tumor samples showed that the treatment 
of these compounds significantly inhibited the immunostaining for PCNA (Figs. 3aand 3b). 
Quantification of PCNA staining showed 41.8% (p ≤ 0.001) decrease in proliferation index with 
isosilibinin, 33.3% (p ≤ 0.001) decrease with silymarin treatment and 31.2% (p ≤ 0.001) decrease 
with silibinin treatment when compared with the control group after 53 days of treatment 
(Fig. 3b). However, the differences in the inhibitory effect of isosilibinin, silymarin and silibinin 
on PCNA staining were not statistically significant. Immunohistochemical analysis of the tumor 
tissues showed that even after 24 days of treatments withdrawal reduction in PCNA‐positive 
cells in the isosilibinin group was 32.7% (p≤ 0.001), the silymarin group 21.7% (p = 0.001) and 
silibinin group 19.9% (p ≤ 0.05) relative to that of the control group (Figs. 3a and 3b). These 
results correlate with the decrease seen in the tumor volume even after withdrawal of these 
compounds. 
 
Isosilibinin, silymarin and silibinin treatment induce apoptosis in DU145 xenografts 
 
Next, we examined the effect of these compounds on apoptosis induction in xenograft tissue 
(after 53 days of treatment) by TUNEL staining. The results showed that isosilibinin treatment 
increased the apoptotic cell population by 2.4‐fold (p ≤ 0.001), whereas silymarin and silibinin 
increased the apoptotic cell population by 2.1‐fold (p ≤ 0.001) and 1.8‐fold (p = 0.05), 
respectively, when compared with the control group (Figs. 3c and 3d). There was however no 
significant difference in the apoptotic cell population between control and different treatment 
groups after 24 days of treatments withdrawal (data not shown). 
 
 
 
Figure 3. In vivo anti‐proliferative and pro‐apoptotic effects of isosilibinin, silymarin and silibinin in DU145 tumor 
xenografts in nude mice. (a, b) At the end of 53 days and 77 days mice were sacrificed and tumor tissues were 
analyzed for immunohistochemical staining of proliferating cell nuclear antigen (PCNA) and photomicrographs 
were taken as detailed in the “Material and methods”. The representative images shown are from 77 days tumor 
tissue. Proliferation index was calculated as number of PCNA positive cells × 100/total number of cells counted 
under ×400 magnification in 5 randomly selected areas in each tumor sample. Statistical significance shown for 
isosilibinin, silymarin and silibinin is with respect to corresponding controls (53 or 77 days). (c, d) Apoptotic cell 
population in various groups after 53 days of treatment was measured by TUNEL assay as detailed in the “Material 
and methods”. Apoptotic index was calculated as number of positive cells × 100/total number of cells counted under 
×400 magnification in 5 randomly selected areas in each tumor sample. The data shown in the bar diagram 
represents mean and ± SEM (error bars) of 4–5 samples for each group. Abbreviations: C, control; Isosil, 
isosilibinin; SM, silymarin; SB, silibinin. *, p ≤ 0.001; #, p ≤ 0.01; $, p ≤ 0.05. 
 
Isosilibinin, silymarin and silibinin inhibit angiogenesis in DU145 xenograft 
 
Earlier studies have shown that silymarin and silibinin possess strong anti‐angiogenic activity,23-
25 so we next analyzed the tumors for CD31 staining to assess tumor microvessel density. The 
immunohistochemical analysis of tumor tissues (53 days treatment) showed that isosilibinin 
treatment decreased the CD31‐positive (brown) cells by 43% (p ≤ 0.01), whereas silymarin and 
silibinin decreased by 36.2% (p ≤ 0.05) and 39.4% (p ≤ 0.01), respectively (Figs. 4a and 4b). 
There were no significant differences in the CD31‐positive cells in tumors between different 
groups 24 days after treatment was discontinued (data not shown). 
 
Isosilibinin, silymarin and silibinin inhibit VEGF expression in DU145 xenograft 
 
VEGF is an important angiogenic factor, which is secreted by tumor cells and regulate the tumor 
vascularization.26, 27 Because we observed a strong decrease in tumor microvessel density with 
all 3 formulations, we next examined the tumor tissues for VEGF immunostaining. Results 
showed that 53 days of isosilibinin treatment resulted in 45.6% (p ≤ 0.001) decrease in VEGF 
immunoreactivity, whereas silymarin and silibinin treatment decreased the VEGF 
immunoreactivity by 40% (p ≤ 0.01) and 34.4% (p ≤ 0.05) respectively (Figs. 4c and 4d). There 
was no statistically significant difference in VEGF staining between different groups 24days 
after the treatment was stopped (data not shown). 
 
 
Figure 4. In vivo effect of isosilibinin, silymarin and silibinin on microvessel density and VEGF level in DU145 
tumor xenografts in athymic nude mice. At the end of 53 days treatment, 7 mice from each group were sacrificed 
and tumor tissues were analyzed by immunohistochemical staining for CD31 (a, b) and VEGF (c, d) as detailed in 
the “Materials and methods”. For microvessel density CD31 positive cells were counted at ×400 field in 5 randomly 
selected areas in each tumor sample. VEGF immunoreactivity (represented by brown staining) was analyzed in 5 
random areas for each tumor tissue and was scored as 0+ (no staining), 1+ (weak staining), 2+ (moderate staining), 
3+ (strong staining), 4+ (very strong staining). The data shown in the bar diagram represents mean and ± SEM (error 
bars) of 4–5 samples for each group. Abbreviations: C, control; Isosil, isosilibinin; SM, silymarin; SB, silibinin. 
*, p ≤ 0.001; #, p ≤ 0.01; $, p ≤ 0.05. 
 
Isosilibinin, silymarin and silibinin differentially modulate cell cycle regulators in DU145 
xenograft 
 
The cell cycle is regulated by the interaction of various factors involving cyclins and cyclin‐
dependent kinases (Cdks).28-30 Cell cycle deregulation has been considered as hallmark of cancer 
cells and is 1 of the factors underlying their unlimited replicative potential.31 Next, we examined 
the effect of these compounds on the expression of various cell cycle regulators in both set of 
tumor tissues (53 days and 77 days) by Western blot analysis. Results showed that these 
compounds have differential effects on the expression of cell cycle regulators (Figs. 5a and 5b). 
Isosilibinin and silibinin significantly decreased cyclin A levels (p ≤ 0.05), whereas silymarin 
had no significant effect on cyclin A levels (Fig. 5a). Silibinin treatment inhibited cyclin D1 
expression (p ≤ 0.001), whereas isosilibinin and silymarin treatment did not have any significant 
effect on cyclin D1 levels (Fig. 5a). All three compounds significantly inhibited the cyclin D3 
and cyclin E levels in tissues from 53 days experiment (p ≤ 0.001) (Fig. 5a). None of the 
formulations significantly affected the levels of cyclins (A, D1, D3 and E) in tumor tissue from 
the 77 days experiment (24 days treatment‐free; Fig. 5a). 
 
 
Figure 5. Effect of isosilibinin, silymarin and silibinin on cell cycle regulatory molecules in DU145 tumor 
xenografts in athymic nude mice. Two randomly selected samples from each group in 53 days and 77 days xenograft 
study were analyzed for cell cycle regulatory molecules. Lysates were prepared and Western blot analysis was 
performed for (a) cyclin A, cyclin D1, cyclin D3 and cyclin E, (b) Cdk2, Cdk 4 and Cdk6 as detailed in the 
“Material and methods.” The experiment was repeated at least once with fresh set of samples. The densitometric 
value of each band was analyzed by the Scion Image program and represented as a bar diagram. The data shown in 
the bar diagram represents mean and ± SEM (error bars) of 4 samples for each group. Abbreviations: C, control; 
Isosil, isosilibinin; SM, silymarin; SB, silibinin. *, p ≤ 0.001; #, p ≤ 0.01; $, p ≤ 0.05. 
 
These formulations also targeted the expression of Cdks in the tumor tissue. Treatment with all 
the 3 of the formulations suppressed the expression of Cdk4 and Cdk6, but did not affect the 
Cdk2 level in the 53 days tumor tissues (p ≤ 0.001 to p ≤ 0.01) (Fig. 5b). The isosilibinin and 
silibinin groups had significantly lower expression of Cdk2 only after 24 days of withdrawal of 
treatment (p ≤ 0.001 to p ≤ 0.05) (Fig. 5b). Only silibinin treatment was effective in inhibiting 
the Cdk6 level in the 77 days tumor tissue (p ≤ 0.05) (Fig. 5b). 
 
Discussion 
 
Phytochemicals based cancer management has been suggested as an attractive strategy against 
PCa, 1 of the leading cause of cancer‐related mortality and morbidity around the world 
especially in the western countries.1, 7, 32, 33 Silymarin, also known as milk thistle extract, has 
shown promise and potential as an ideal anti‐cancer agent.12, 34 Silymarin has been traditionally 
known for its hepatoprotective properties and used for reducing the toxicity related with alcohol, 
metals, mycotoxins, chemotherapy, radiotherapy, etc.35 Extensive research within the last decade 
has shown that silymarin and its active semi‐purified fraction silibinin inhibit PCa growth and 
progression in both in vitro and in vivomodels.12, 13, 25, 30 Silymarin and silibinin have been shown 
to inhibit the PSA secretion by PCa LNCaP cells by targeting the function of androgen 
receptor.36, 37 The anti‐tumorigenic action of silymarin has been related with its inhibitory effect 
on erbB1 receptor signaling.38 Studies have also shown that silymarin and silibinin activate 
cellular checkpoints and Cdk inhibitors along with inhibition of Cdks activity, thus halting the 
cell cycle to either G1 and/or G2M phase.30, 38, 39 Silymarin treatment has been reported to inhibit 
the 3,2‐dimethyl‐4‐aminobiphenyl (DMAB)‐induced prostate carcinogenesis in male F344 
rats.40 Silibinin has been shown to inhibit the growth of PCa cells in xenograft studies as well as 
in the transgenic adenocarcinoma of the mouse prostate model.13, 25, 41 As a result of these 
preclinical studies, the efficacy of silibinin (as the Siliphos formulation with 
phosphatidylcholine) is being evaluated in Phase II clinical trial in PCa patients, after the 
successful completion of Phase I trial.42 Despite this progress in milk thistle research, the relative 
contribution of other constituents of silymarin to its efficacy remains largely unknown. 
 
The present is the first study to demonstrate the in vivo growth inhibitory potential of isosilibinin, 
a diastereoisomeric two‐compound formulation from silymarin. The present study clearly 
showed that isosilibinin treatment inhibited advanced human PCa DU145 xenograft growth in 
athymic nude mice, which was equally good, when compared with silymarin or relatively better 
(without statistical significance) when compared with silibinin. One particularly notable finding 
of the present study is that even after 24 days of withdrawal of the treatment agents, tumor 
volumes remain decreased in isosilibinin, silymarin and silibinin treated groups, suggesting that 
there would not be a compensatory tumor growth even after withdrawal of these compounds. 
Earlier studies have shown the excellent safety profile of silymarin and silibinin, and both are 
known to be nontoxic even at higher doses.42-44 In fact, rodent LD50 values have never been 
achieved for silibinin or silymarin. The present study illustrates for the first time the nontoxic 
nature of isosilibinin at the dose level used. 
 
The study of cancer‐related biomarkers has been suggested as a critical element in understanding 
the clinical relevance of chemopreventive agents.45, 46 In the present study, we focused on 3 
surrogate biomarkers, namely cell proliferation, apoptosis and angiogenesis, which are widely 
used and linked to the growth and progression of cancer, including PCa.25, 45, 47 The level of 
cellular PCNA is regarded as 1 of the markers for cellular proliferation.48 PCNA is a 36 kDa 
auxiliary protein to DNA polymerase and it was identified as an antigen that is expressed in the 
nuclei of cells during the DNA synthesis phase of cell cycle. In the present study, isosilibinin, 
silymarin and silibinin treatment each significantly inhibited the PCNA levels in xenograft 
tissue. These results are correlated with the decreased tumor volume observed with the treatment 
of these formulations. 
 
Apoptosis evasion has been suggested as 1 of the hallmark of cancer cells.31 Advanced human 
PCa including DU145 cells are known to have constitutively active survival signaling pathways, 
rendering these cells apoptosis‐resistant.49 Treatment with isosilibinin, silymarin or silibinin 
significantly increased the apoptotic cell population in the xenograft tissue as measured by 
TUNEL staining. Even though this might not be the main mechanism of action for these 
compounds, as apoptotic cell population remained less than 5% of total cells, it could be 
contributing partly to their overall antitumor effects. 
 
Angiogenesis is 1 of the important elements in the process of tumorigenesis and is considered 
essential for the growth and progression of cancer cells.45, 50, 51 It has been reported that 
angiogenesis is especially critical for the growth and progression of solid tumors, as tumor 
growth beyond 2–3 mm size is often preceded by increased formation of new blood 
vessels.45, 51 Therefore, targeting angiogenesis represents 1 of the most promising approaches to 
control tumor growth.45 The present study revealed that isosilibinin followed by silibinin and 
silymarin were effective in inhibiting the microvessel density in the tumor xenograft, suggesting 
their antiangiogenic efficacy against advanced PCa. Studies have shown that process of neo‐
angiogenesis is highly complex and tightly regulated by multiple pro‐angiogenic and anti‐
angiogenic factors. One of the important pro‐angiogenic factors is VEGF, which is expressed 
and secreted by advanced cancer cells and promotes endothelial cell proliferation, migration and 
differentiation to initiate as well as maintain tumor angiogenesis.26, 27 In the present study, 
isosilibinin, silymarin and silibinin treatment strongly inhibited VEGF expression in the tumor 
tissue, which might contribute to the decreased microvessel density observed with their 
treatments. 
 
Aberrant cell cycle regulation has been recognized as the characteristic of cancers including 
PCa.31 Earlier studies have suggested cell cycle control as the basis for cancer chemoprevention 
through phytochemicals and dietary agents.52, 53 Therefore, cancer chemopreventive agents have 
been routinely screened for their efficacy to target cell cycle regulatory determinants in cancer 
cells. We have reported that silymarin and its constituents regulate the expression of various cell 
cycle regulatory molecules and cause cell cycle arrest in PCa cells.18, 30 The present in vivo data 
also confirms that these formulations have differential effects on the expression of cell cycle 
regulatory molecules. These studies further confirm that these formulations, even though closely 
related chemically, might have subtle differences in their mechanism of action; but further 
studies are warranted to clearly understand these aspects. 
 
In conclusion, the present study is the first to demonstrate that isosilibinin treatment inhibits the 
growth of advanced human PCa cells in vivo without any toxicity. This potency of isosilibinin 
was either equal to or better than silymarin/silibinin. Isosilibinin was also shown to possess in 
vivo anti‐proliferative, anti‐angiogenic, pro‐apoptotic and cell cycle modulatory properties. 
Further studies are needed to clearly understand the mechanism of action for isosilibinin alone or 
isosilibinin‐enriched silymarin formulations for their clinical utility against PCa. 
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